Theravance Biopharma (TBPH) Revenue (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Revenue data on file, last reported at $17.7 million in Q1 2026.

• On a quarterly basis, Revenue rose 15.02% year-over-year to $17.7 million in Q1 2026; TTM through Mar 2026 was $109.8 million, a 68.2% increase from a year earlier, with the FY2025 full-year figure at $7.5 million, down 88.35% from the prior year.
• Revenue for Q1 2026 stood at $17.7 million, down from $45.9 million in the prior quarter.
• Over the last five years, Revenue for TBPH reached as high as $45.9 million in Q4 2025 and fell as low as $10.4 million in Q1 2023.
• Historically, Revenue has averaged $17.5 million across 5 years, with a median of $15.4 million in 2025.
• Across the five-year window, Revenue dropped 21.06% in 2023 and surged 144.7% in 2025, its largest moves.
• Year by year, Revenue stood at $14.6 million in 2022, then gained by 19.91% to $17.6 million in 2023, then advanced by 6.77% to $18.8 million in 2024, then jumped by 144.7% to $45.9 million in 2025, then tumbled by 61.43% to $17.7 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $17.7 million in Q1 2026, $45.9 million in Q4 2025, and $20.0 million in Q3 2025.